Savara (SVRA) Competitors $2.69 0.00 (0.00%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$2.68 0.00 (-0.19%) As of 02/21/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SVRA vs. JANX, AGIO, NAMS, IDYA, SDGR, TVTX, BLTE, VERA, PRAX, and DVAXShould you be buying Savara stock or one of its competitors? The main competitors of Savara include Janux Therapeutics (JANX), Agios Pharmaceuticals (AGIO), NewAmsterdam Pharma (NAMS), IDEAYA Biosciences (IDYA), Schrödinger (SDGR), Travere Therapeutics (TVTX), Belite Bio (BLTE), Vera Therapeutics (VERA), Praxis Precision Medicines (PRAX), and Dynavax Technologies (DVAX). These companies are all part of the "pharmaceutical preparations" industry. Savara vs. Janux Therapeutics Agios Pharmaceuticals NewAmsterdam Pharma IDEAYA Biosciences Schrödinger Travere Therapeutics Belite Bio Vera Therapeutics Praxis Precision Medicines Dynavax Technologies Janux Therapeutics (NASDAQ:JANX) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, community ranking, risk, valuation, earnings and dividends. Which has more volatility and risk, JANX or SVRA? Janux Therapeutics has a beta of 3.16, indicating that its share price is 216% more volatile than the S&P 500. Comparatively, Savara has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Does the media refer more to JANX or SVRA? In the previous week, Savara had 1 more articles in the media than Janux Therapeutics. MarketBeat recorded 1 mentions for Savara and 0 mentions for Janux Therapeutics. Savara's average media sentiment score of 1.02 beat Janux Therapeutics' score of 0.00 indicating that Savara is being referred to more favorably in the news media. Company Overall Sentiment Janux Therapeutics Neutral Savara Positive Is JANX or SVRA more profitable? Savara has a net margin of 0.00% compared to Janux Therapeutics' net margin of -463.91%. Janux Therapeutics' return on equity of -10.47% beat Savara's return on equity.Company Net Margins Return on Equity Return on Assets Janux Therapeutics-463.91% -10.47% -9.86% Savara N/A -58.89%-46.44% Do institutionals and insiders believe in JANX or SVRA? 75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 29.4% of Janux Therapeutics shares are owned by insiders. Comparatively, 5.1% of Savara shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has higher earnings and valuation, JANX or SVRA? Savara has lower revenue, but higher earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanux Therapeutics$13.05M144.83-$58.29M-$1.17-30.78SavaraN/AN/A-$54.70M-$0.43-6.26 Do analysts prefer JANX or SVRA? Janux Therapeutics presently has a consensus target price of $89.90, suggesting a potential upside of 149.65%. Savara has a consensus target price of $9.86, suggesting a potential upside of 266.44%. Given Savara's higher possible upside, analysts plainly believe Savara is more favorable than Janux Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.08Savara 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Does the MarketBeat Community believe in JANX or SVRA? Savara received 258 more outperform votes than Janux Therapeutics when rated by MarketBeat users. However, 71.19% of users gave Janux Therapeutics an outperform vote while only 66.82% of users gave Savara an outperform vote. CompanyUnderperformOutperformJanux TherapeuticsOutperform Votes4271.19% Underperform Votes1728.81% SavaraOutperform Votes30066.82% Underperform Votes14933.18% SummaryJanux Therapeutics and Savara tied by winning 9 of the 18 factors compared between the two stocks. Get Savara News Delivered to You Automatically Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SVRA vs. The Competition Export to ExcelMetricSavaraPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$461.65M$7.07B$5.85B$9.15BDividend YieldN/A2.76%4.76%3.85%P/E Ratio-6.262.5616.5114.19Price / SalesN/A304.55450.0276.60Price / CashN/A65.6738.0134.95Price / Book2.596.717.644.63Net Income-$54.70M$138.11M$3.18B$245.69M7 Day Performance-4.61%-2.54%-1.95%-2.68%1 Month Performance-2.89%-2.00%-0.23%-2.16%1 Year Performance-45.21%-5.04%16.69%12.90% Savara Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SVRASavara2.1216 of 5 stars$2.69flat$9.86+266.4%-44.0%$461.65MN/A-6.26N/APositive NewsJANXJanux Therapeutics3.1354 of 5 stars$36.37-2.2%$89.90+147.2%+174.0%$1.91B$13.05M-31.0930AGIOAgios Pharmaceuticals4.3488 of 5 stars$33.22-0.2%$56.33+69.6%+31.4%$1.89B$26.82M2.92390Earnings ReportShort Interest ↓NAMSNewAmsterdam Pharma3.2873 of 5 stars$19.91+2.6%$41.60+108.9%-13.9%$1.84B$14.09M0.004Upcoming EarningsIDYAIDEAYA Biosciences3.8397 of 5 stars$21.00+1.2%$53.58+155.2%-50.9%$1.82B$23.39M-9.0180Gap UpSDGRSchrödinger1.793 of 5 stars$24.85+1.7%$32.11+29.2%-24.6%$1.81B$216.67M-10.62790Upcoming EarningsTVTXTravere Therapeutics2.9586 of 5 stars$22.91-3.4%$27.77+21.2%+178.9%$1.79B$145.24M-5.04460Earnings ReportAnalyst ForecastNews CoverageGap DownBLTEBelite Bio3.2178 of 5 stars$56.00-1.0%$96.33+72.0%+26.3%$1.78BN/A-50.4510VERAVera Therapeutics2.261 of 5 stars$27.46-19.7%$65.44+138.3%-35.8%$1.74BN/A-10.5240High Trading VolumePRAXPraxis Precision Medicines1.9375 of 5 stars$90.77+4.7%$145.20+60.0%+84.0%$1.69B$2.45M-8.81110DVAXDynavax Technologies4.2781 of 5 stars$12.82+1.0%$21.50+67.7%+7.0%$1.69B$232.28M98.62350Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap Up Related Companies and Tools Related Companies JANX Alternatives AGIO Alternatives NAMS Alternatives IDYA Alternatives SDGR Alternatives TVTX Alternatives BLTE Alternatives VERA Alternatives PRAX Alternatives DVAX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SVRA) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Savara Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Savara With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SVRA Stock Alerts